<div id="readability-page-1"><p>Bahl &amp; Gaynor Inc. raised its holdings in shares of  Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 15.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor  owned 2,526,930 shares of the company's stock after purchasing an additional 338,839 shares during the period. Johnson &amp; Johnson accounts for approximately  2.0% of Bahl &amp; Gaynor Inc.'s investment portfolio, making the stock its 12th biggest holding. Bahl &amp; Gaynor Inc. owned about 0.10% of Johnson &amp; Johnson worth $385,989,000 at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>Johnson &amp; Johnson</strong> alerts:</span></p></div><ul><li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li></ul><p>A number of other institutional investors have also recently made changes to their positions in JNJ. GFG Capital LLC purchased a new stake in  Johnson &amp; Johnson in the second quarter valued at about $35,000.  Stone House Investment Management LLC acquired a new position in shares of  Johnson &amp; Johnson during the first quarter valued at about $47,000.  1248 Management LLC purchased a new position in shares of  Johnson &amp; Johnson in the 1st quarter valued at approximately $48,000.  Harvest Fund Management Co. Ltd acquired a new stake in  Johnson &amp; Johnson in the 1st quarter worth approximately $52,000.  Finally, Pandora Wealth Inc. purchased a new stake in  Johnson &amp; Johnson during the 1st quarter worth approximately $65,000. Institutional investors and hedge funds own  69.55% of the company's stock. </p><h2>Johnson &amp; Johnson Stock Performance</h2><p>Shares of JNJ stock opened at $203.88 on Friday. Johnson &amp; Johnson has a 52-week low of $140.68 and a 52-week high of $206.94. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The stock has a market cap of $491.21 billion, a PE ratio of 19.68, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. The business has a 50-day simple moving average of $188.25 and a 200-day simple moving average of $171.55. </p><ul><li>3 Smart Defensive Stocks for an Uneasy Market</li></ul><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson &amp; Johnson had a return on equity of 32.73% and a net margin of 27.26%.The company had revenue of $24.02 billion during the quarter.  On average, equities analysts expect that  Johnson &amp; Johnson will post 10.58 EPS for the current year. </p><h2>Johnson &amp; Johnson Dividend Announcement</h2><p>The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Tuesday, November 25th. Johnson &amp; Johnson's payout ratio is currently 50.19%. </p><h2>Insider Buying and Selling</h2><ul><li>Hold Ratings, High Rewards? 3 Stocks That Could Defy Expectations</li></ul><p>In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own  0.16% of the company's stock. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of research analysts have issued reports on the stock. Scotiabank assumed coverage on shares of Johnson &amp; Johnson in a report on Thursday, November 13th. They issued a &#34;sector outperform&#34; rating and a $230.00 price target for the company. Cowen  restated a &#34;buy&#34; rating on shares of Johnson &amp; Johnson in a research note on Tuesday, October 14th. Morgan Stanley  set a $190.00 price target on Johnson &amp; Johnson in a research note on Wednesday, October 15th. Wall Street Zen upgraded Johnson &amp; Johnson from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, September 13th. Finally, Guggenheim upgraded Johnson &amp; Johnson from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and upped their target price for the company from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Four research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have issued  a Hold rating to the stock. According to MarketBeat, the stock  has an average rating of &#34;Moderate Buy&#34; and an average price target of $201.05.</p><p><b>Check Out Our Latest Report on JNJ</b></p><h2>About Johnson &amp; Johnson</h2> (Free Report)<p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p><h2>Read More</h2><ul><li>Five stocks we like better than Johnson &amp; Johnson</li><li>3 Tickers Leading a Meme Stock Revival</li><li>A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves</li><li>How to Use the MarketBeat Stock Screener </li><li>12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming</li><li>What is the Euro STOXX 50 Index?</li><li>Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Bahl & Gaynor Inc. increased its holdings in Johnson & Johnson by 15.5% in Q2, now owning 2,526,930 shares worth $385.99 million. This makes J&J 2.0% of their portfolio and their 12th largest holding. Other institutional investors also made changes to their J&J positions. J&J's stock opened at $203.88, with a market cap of $491.21 billion. The company reported $2.26 EPS for Q2 and announced a quarterly dividend of $1.30 per share. Several analysts have given J&J a buy rating.</p>

Johnson & Johnson $JNJ Shares Bought by Bahl & Gaynor Inc.